On Dec. 10, the U.S. Food and Drug Administration expanded the approved use of Zytiga (abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer before receiving chemotherapy. Read more.
FDA expands Zytiga’s use for late-stage breast cancer
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
